The UK-wide initiative brings together 10 specialist research centres to study human lymph nodes, with a focus on improving vaccine development, understanding immune responses and advancing treatments for autoimmune and inflammatory diseases.
A new £1.7 million UK-wide research network dedicated to understanding the role of lymph nodes in infection, immunity and inflammatory disease has been launched. The initiative, called Lymph Node Research UK, is led by the University of Oxford, Cardiff University and Newcastle University, and is backed by funding from UK Research and Innovation (UKRI). The network aims to strengthen the UK’s position in human lymph node research and accelerate discoveries in immunology, vaccine development and disease prevention.
The development is significant because lymph nodes are central to how the immune system responds to infections, vaccines, cancer and autoimmune conditions. Researchers say a better understanding of these processes could support the development of safer vaccines and new therapies for infectious, inflammatory and autoimmune diseases.
Why lymph nodes matter
Lymph nodes are small bean-shaped organs that serve as hubs of the immune system. They help defend the body against infections, cancer and autoimmune diseases by coordinating immune responses.
Following vaccination or infection, lymph nodes often enlarge as millions of immune cells gather and multiply within them. Scientists believe studying these processes in greater detail could reveal how immune responses are generated and regulated.
According to the network, insights from lymph node research could help improve the efficiency and safety of vaccine development. The work may also support the discovery of new treatments for infectious diseases and inflammatory conditions.
Ten specialist centres join the network
In addition to the three lead institutions, specialist centres have been established at University of Birmingham; University College London (UCL); University of Liverpool; University of Glasgow; St. George’s Vaccine Institute; MRC Toxicology Unit, University of Cambridge; Cambridge Stem Cell Institute and University of Cambridge. The network said additional partners are expected to join in the future.
Advances in technology open new opportunities
The launch comes at a time when advances in medical technologies have made human lymph node research more accessible.
Developments in ultrasound imaging and minimally invasive sampling methods, including fine needle aspiration, now allow researchers to study human lymph nodes in unprecedented detail. These techniques provide new opportunities to examine how the immune system responds to infection, vaccination and disease in real-world settings.
Fine needle aspiration is a minimally invasive procedure that uses a thin needle to collect cells or fluid from a lymph node for analysis.
Professor Katrina Pollock, Chief Investigator for Lymph Node Research UK at the Oxford Vaccine Group, University of Oxford, said the network represented a major step forward for the field.
“This marks an exciting milestone for the rapidly growing field of human lymph node research and reflects years of previous development, now enabling us to harness the strength of collaboration between our partners.”
Pollock said the initiative would help build the infrastructure needed to support globally impactful research in immunology, vaccine development and disease prevention.
Potential implications for autoimmune diseases
Researchers also expect the network to contribute to a better understanding of autoimmune conditions.
According to the network, lymph node research could help identify new therapeutic approaches for autoimmune and inflammatory diseases, including rheumatoid arthritis, a chronic autoimmune condition that currently has no cure.
Dr Lucy Jones, Clinical Senior Lecturer at Cardiff University School of Medicine, said the funding would support the creation of a Welsh Lymph Node Research Hub and strengthen collaborations across the country.
She said the network’s research could benefit patients affected by infectious diseases, autoimmune disorders and age-related immune decline.
Jones added that a coordinated national network could drive progress in infection and immunity research, drug and vaccine development, commercial partnerships and cancer research.
Existing studies already exploring new treatments
At Newcastle University, researchers are already studying lymph nodes in clinical trials investigating new treatments for rheumatoid arthritis.
Professor John Isaacs, Principal Investigator for Lymph Node Research UK at Newcastle University, said understanding the biological events occurring within human lymph nodes could lead to improved therapies for autoimmune and inflammatory diseases.
“Our own research is already sampling lymph nodes, for example in trials of AuToDeCRA, the treatment we are developing to switch off rheumatoid arthritis,” Isaacs said.
AuToDeCRA stands for AUtologous TOlerogenic DEndritic Cells for Rheumatoid Arthritis, an investigational treatment approach being studied for its potential to modulate immune responses in rheumatoid arthritis.
Building a national research platform
The launch of Lymph Node Research UK reflects growing scientific interest in understanding human immune responses directly within lymph nodes. Researchers believe the network will provide a platform for collaborative studies spanning infection, immunity, vaccine science, cancer research and autoimmune disease.
As advances in imaging and sampling technologies continue to expand research capabilities, the network aims to generate evidence that could inform future vaccines, immunotherapies and treatments for inflammatory diseases.
